Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...
Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...
pTau217, also called phosphorylated tau at threonine 217, is a specific blood-based biomarker for brain amyloid β pathology. When validated against CSF Aβ42/40 and PET imaging, the biomarker showed ...
TORONTO — An expert panel convened by the Alzheimer’s Association has released the first clinical guidelines to help clinicians choose the most appropriate blood-based biomarker (BBM) test to aid in ...
Novel chemical series, headlined by advanced lead GT-04686, is ready for IND-enabling studies for the treatment of Parkinson’s disease and other neurological disorders BETHESDA, Md., March 18, 2026 ...
Today's post will focus on the neuropeptide vasopressin and its potential role as a biomarker in autism spectrum disorder (ASD). Vasopressin and other neuropeptides have been a common topic on this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results